ArticleVaccines2026
Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios.
Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThe aim was to evaluate the cost-effectiveness of self-paid vaccination using Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV) in China, as well as their inclusion in China's National Immunization Program (NIP), and to determine the most cost-effective initial vaccination age under this inclusion strategy.
methodsBased on the ZONA model, a Markov model was developed by incorporating pain severity levels for herpes zoster (HZ) and postherpetic neuralgia (PHN), allowing for dynamic transitions between health states. The model evaluated the cost-effectiveness of six vaccination strategies from a societal perspective. Economic evaluations were conducted using the incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and incremental cost-utility ratio (ICUR). The robustness of the results was verified through sensitivity analysis.
resultsIn the self-paid scenario, both RZV and ZVL were economically viable for preventing HZ. However, neither was cost-effective in preventing PHN. When included in the NIP, initiating RZV vaccination at age 50 demonstrated dominance (higher quality-adjusted life years and lower costs), with an ICER of -3826 CNY per HZ case prevented, -38,669 CNY per PHN case prevented, and an ICUR of -11,128 CNY per QALY gained. Subgroup analysis indicated that initiating RZV vaccination at age 50 offered the best cost-effectiveness, while age 70 was the most cost-saving option.
conclusionsGenerally, RZV demonstrates greater cost-effectiveness compared to ZVL. Incorporating RZV into the NIP, starting at age 70, is the optimal strategy to reduce the burden of HZ and PHN and improve healthcare resource allocation in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.